Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease

References

• JTibble, KTeahon, BThjodleifsson, ARoseth, GSigthorsson, SBridger, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000;47:506–13.
   PubMed Web of Science ®Google Scholar
• TSipponen. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis 2013;31:336–44.
   PubMed Web of Science ®Google Scholar
• AGRoseth, MKFagerhol, EAadland, HSchjonsby. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793–8.
   PubMed Web of Science ®Google Scholar
• HTon, Brandsnes SDale, JHoltlund, ESkuibina, HSchjonsby, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41–54.
   PubMed Web of Science ®Google Scholar
• ADamms, SCBischoff. Validation and clinical significance of a new calprotectin rapid teswt for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis 2008;23:985–92.
   PubMed Web of Science ®Google Scholar
• TAVestergaard, SNielsen, JFDahlerup, NHornung. Fecal calprotecton:assessment of a rapid test. Scand J Clin Lab Invest 2008;68:343–7.
   PubMed Web of Science ®Google Scholar
• CMOtten, LKok, BJWitteman, RBaumgarten, EKampman, KGMoons, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med 2008;46:1275–80.
   PubMed Web of Science ®Google Scholar
• JHessels, GDouw, DDYildirim, GMeerman, MAvan Herwaarden, FAvan den Bergh. Evaluation of prevent ID and quantum blue rapid tests for fecal calprotectin. Clin Chem Lab Med 2012;50:1079–82.
   PubMed Web of Science ®Google Scholar
• KLKolho, DTurner, GVeereman-Wauters, MSladek, Lde Ridder, RShaoul, et al. Rapid test for fecal calprotectin levels in children with Crohn’s disease. J Pediatr Gastroenterol Nutr 2012;55:436–9.
   PubMed Web of Science ®Google Scholar
• JATibble, GSigthorsson, RFoster, IForgacs, IBjarnason. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450–60.
   PubMed Web of Science ®Google Scholar
• ACarroccio, GIacono, MCottone, LDi Prima, FCartabellotta, FCavataio, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003;49:861–7.
   PubMed Web of Science ®Google Scholar
• FCosta, MGMumolo, MBellini, MRRomano, LCeccarelli, PArpe, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642–7.
   PubMedGoogle Scholar
• SDolwani, MMetzner, JJWassell, AYong, ABHawthorne. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20:615–21.
   PubMed Web of Science ®Google Scholar
• RD’Inca, EDal Pont, VDi Leo, AFerronato, WFries, MGVettorato, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22:429–37.
   PubMed Web of Science ®Google Scholar
• AMSchoepfer, MTrummler, PSeeholzer, BSeibold-Schmid, FSeibold. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14:32–9.
   PubMed Web of Science ®Google Scholar
• OSchroder, MNaumann, YShastri, NPovse, JStein. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 2007;26:1035–42.
   PubMed Web of Science ®Google Scholar
• ULFagerberg, LLoof, UMyrdal, LOHansson, YFinkel. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005;40:450–5.
   PubMed Web of Science ®Google Scholar
• IDKostakis, KGCholidou, AGVaiopoulos, ISVlachos, DPerrea, GVaos. Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review. Dig Dis Sci 2013;58:309–19.
   PubMed Web of Science ®Google Scholar
• ACvon Roon, LKaramountzos, SPurkayastha, GEReese, AWDarzi, JPTeare, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803–13.
   PubMed Web of Science ®Google Scholar
• PFvan Rheenen, EVan de Vijver, VFidler. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:3369.
   PubMed Web of Science ®Google Scholar
• PHenderson, NHAnderson, DCWilson. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: A systematic review and meta-analysis. Am J Gastroenterol 2014;109:637–45.
   PubMed Web of Science ®Google Scholar
• PPavlidis, FJChedgy, JATibble. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scand J Gastroenterol 2013;48:1048–54.
   PubMed Web of Science ®Google Scholar
• DWalkiewicz, SLWerlin, DFish, MScanlon, PHanaway, SKugathasan. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008;14:669–73.
   PubMed Web of Science ®Google Scholar
• GD’Haens, MFerrante, SVermeire, FBaert, MNoman, LMoortgat, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218–24.
   PubMed Web of Science ®Google Scholar
• AGRoseth, EAadland, JJahnsen, NRaknerud. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176–80.
   PubMed Web of Science ®Google Scholar
• SKBunn, WMBisset, MJMain, BEGolden. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;32:171–7.
   PubMed Web of Science ®Google Scholar
• AMSchoepfer, CBeglinger, AStraumann, MTrummler, PRenzulli, FSeibold. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009;15:1851–8.
   PubMed Web of Science ®Google Scholar
• SKBunn, WMBisset, MJMain, ESGray, SOlson, BEGolden. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:14–22.
   PubMed Web of Science ®Google Scholar
• AGRoseth, EAadland, KGrzyb. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017–20.
   PubMed Web of Science ®Google Scholar
• TSipponen, ESavilahti, KLKolho, HNuutinen, UTurunen, MFarkkila. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40–6.
   PubMed Web of Science ®Google Scholar
• TSipponen, KLKolho. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol 2010;45:872–7.
   PubMed Web of Science ®Google Scholar
• BThjodleifsson, GSigthorsson, NCariglia, IReynisdottir, DFGudbjartsson, KKristjansson, et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn’s disease relatives? Gastroenterology 2003;124:1728–37.
   PubMed Web of Science ®Google Scholar
• BMoum, JJahnsen, TBernklev. Fecal calprotectin variability in Crohn’s disease. Inflamm Bowel Dis 2010;16:1091–2.
   PubMed Web of Science ®Google Scholar
• TSipponen, PKarkkainen, ESavilahti, KLKolho, HNuutinen, UTurunen, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther 2008;28:1221–9.
   PubMed Web of Science ®Google Scholar
• JLanghorst, SElsenbruch, JKoelzer, ARueffer, AMichalsen, GJDobos. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-Elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162–9.
   PubMed Web of Science ®Google Scholar
• AMSchoepfer, CBeglinger, AStraumann, MTrummler, SRVavricka, LEBruegger, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162–9.
   PubMed Web of Science ®Google Scholar
• CGBjorkesten, UNieminen, UTurunen, PArkkila, TSipponen, MFarkkila. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol 2012;47:528–37.
   PubMed Web of Science ®Google Scholar
• SPaul, EDel Tedesco, HMarotte, MRinaudo-Gaujous, AMoreau, JMPhelip, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013;19:2568–76.
   PubMed Web of Science ®Google Scholar
• JLin, JChen, JZuo, AYu, ZXiao, FDeng, et al. Meta-analysis: Fecal calprotectin for assessment of infalmmatory bowel disese activity. Inflamm Bowel Dis 2014;20:1407–15.
   PubMed Web of Science ®Google Scholar
• RShaoul, MSladek, DTurner, APaeregaard, GVeres, GVWauters, et al. Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn’s disease. Inflamm Bowel Dis 2012;18:1493–7.
   PubMed Web of Science ®Google Scholar
• PRutgeerts, SVermeire, GVan Assche. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007;56:453–5.
   PubMed Web of Science ®Google Scholar
• BGFeagan, PRutgeerts, BESands, SHanauer, JFColombel, WJSandborn, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• WJSandborn, BGFeagan, CWMarano. Subcutaneous golimumab induces clinical response and remission in patients with moderate to severe ulcerative colitis. Gastroenterology 2014;146:85–95.
   PubMedGoogle Scholar
• PPapay, AIgnjatovic, KKarmiris, HAmarante, PMilheller, BFeagan, et al. Optimising monitoring in the management of Crohn’s disease: a physician’s perspective. J Crohns Colitis 2013;7:653–69.
   PubMed Web of Science ®Google Scholar
• AMSchoepfer, SVavricka, NZahnd-Straumann, AStraumann, CBeglinger. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis 2012;6:412–18.
   PubMed Web of Science ®Google Scholar
• FMRuemmele, JSHyams, AOttley, AGriffiths, KLKolho, JADias, et al. Outcome measures for clinical trials in paediatric IBD: An evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut 2014; 10.1136/gutjnl-2014-307008.
   PubMedGoogle Scholar
• TSipponen, ESavilahti, PKarkkainen, KLKolho, HNuutinen, UTurunen, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis 2008;14:1392–8.
   PubMed Web of Science ®Google Scholar
• AHamalainen, TSipponen, KLKolho. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol 2011;17:5166–71.
   PubMed Web of Science ®Google Scholar
• MDe Vos, ODewit, GD’Haens, FBaert, FFontaine, SVermeire, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis. J Crohns Colitis 2012;6:557–62.
   PubMed Web of Science ®Google Scholar
• PMolander, CGBjorkesten, HMustonen, JHaapamaki, MVauhkonen, KLKolho, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFa blocking agents. Inflamm Bowel Dis 2012;18:2011–17.
   PubMed Web of Science ®Google Scholar
• K-LKolho, TSipponen. The long-term outcome of anti-tumor necrosis factor-alpha therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol 2014;49:434–41.
   PubMed Web of Science ®Google Scholar
• DLaharie, SMesli, FEl Hajbi, EChabrun, EChanteloup, MCapdepont, et al. Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther 2011;34:462–9.
   PubMed Web of Science ®Google Scholar
• CALamb, MKMohiuddin, JGicquel, DNeely, FGBergin, JMHanson, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br J Surg 2009;96:663–74.
   PubMed Web of Science ®Google Scholar
• MScarpa, RD’Inca, DBasso, CRuffolo, LPolese, EBertin, et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn’s disease. Dis Colon Rectum 2007;50:861–9.
   PubMed Web of Science ®Google Scholar
• AOrlando, IModesto, FCastiglione, LScala, DScimeca, ARispo, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn’s disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci 2006;10:17–22.
   PubMedGoogle Scholar
• MWJohnson, SMaestranzi, AMDuffy, DHDewar, AForbes, IBjarnason, et al. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol 2008;20:174–9.
   PubMed Web of Science ®Google Scholar
• MPPakarinen, AKoivusalo, JNatunen, MAshorn, RKarikoski, PAitola, et al. Fecal calprotectin mirrors inflammation of the distal ileum and bowel function after restorative proctocolectomy for pediatric-onset ulcerative colitis. Inflamm Bowel Dis 2010;16:482–6.
   PubMed Web of Science ®Google Scholar
• JATibble, GSigthorsson, SBridger, MKFagerhol, IBjarnason. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15–22.
   PubMed Web of Science ®Google Scholar
• FCosta, MGMumolo, LCeccarelli, MBellini, MRRomano, CSterpi, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 2005;54:364–8.
   PubMed Web of Science ®Google Scholar
• RD’Inca, EDal Pont, VDi Leo, LBenazzato, MMartinato, FLamboglia, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007–14.
   PubMed Web of Science ®Google Scholar
• JPGisbert, FBermejo, JLPerez-Calle, CTaxonera, IVera, AGMcNicholl, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190–8.
   PubMed Web of Science ®Google Scholar
• VGarcia Sanchez, EIglesias Flores, RGonzalez, JPGisbert, JMGallardo-Valverde, AGonzalez-Galilea, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis. J Crohns Colitis 2010;4:144–52.
   PubMedGoogle Scholar
• LKallel, IAyadi, SMatri, MFekih, NBMahmoud, MFeki, et al. Fecal calprotectin is a predictive marker of relapse in Crohn’s disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2010;22:340–5.
   PubMed Web of Science ®Google Scholar
• RMao, YXiao, XGao, BChen, YHe, LYang, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012;18:1894–9.
   PubMed Web of Science ®Google Scholar
• PFvan Rheenen. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis 2012;18:2018–25.
   PubMed Web of Science ®Google Scholar
• KLKolho, DTurner. Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis. ISRN Gastroenterol 2013;2013:179024.
   PubMedGoogle Scholar
• ALasson, MSimren, PStotzer, SIsaksson, LOhman, HStrid. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis 2013;19:576–81.
   PubMed Web of Science ®Google Scholar
• MDe Vos, EJLouis, JJahnsen, JGVandervoort, MNoman, ODewit, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013;19:2111–17.
   PubMed Web of Science ®Google Scholar
• PMolander, MFarkkila, ARistimaki, KSalminen, HKemppainen, TBlomster, et al. Does fecal calprotectin predict short-term relapse after stopping TNFalpha-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis 2014. Available from: http://dx.doi.org/10.1016/jcrohns.2014.06.012.
   Google Scholar
• Nde Suray, JSalleron, GVernier-Massouille, J-Grimaud, YBouhnik, DLaharie, et al. Close monitoring of CRP and fecal calprotectin levels to predict relapse in Crohn’s disease patients. A sub-analysis of the STORI study (Abstract). J Crohns Colitis 2012;6:P274.
   Google Scholar
• GTHo, HMLee, GBrydon, TTing, NHare, HDrummond, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009;104:673–8.
   PubMed Web of Science ®Google Scholar
• DTurner, STLeach, DMack, KUusoue, RMcLernon, JHyams, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010;59:1207–12.
   PubMed Web of Science ®Google Scholar